![Western Blot: CREB3L2 Antibody [NBP1-88697] - S1P inhibition induces autophagy and affects multiple UPR-related TFs. In vitro day 3 B-cells were treated with 10 uM PF-429242 or vehicle control (dH2O) for 72 h and were assessed for cell number using CountBright beads. Shown are the average cell numbers from 7 donors +/- standard deviations. Protein lysates generated from day 3 cells treated for 72 h with 10 uM PF-429242 were evaluated for CREB3L2 and ATF6 by Western blotting. Shown are representative results from 2 donors, a total of 7 donors were evaluated. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/s41598-018-32705-7), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CREB3L2-Antibody-Western-Blot-NBP1-88697-img0008.jpg "Western Blot: CREB3L2 Antibody [NBP1-88697] - S1P inhibition induces autophagy and affects multiple UPR-related TFs. In vitro day 3 B-cells were treated with 10 uM PF-429242 or vehicle control (dH2O) for 72 h and were assessed for cell number using CountBright beads. Shown are the average cell numbers from 7 donors +/- standard deviations. Protein lysates generated from day 3 cells treated for 72 h with 10 uM PF-429242 were evaluated for CREB3L2 and ATF6 by Western blotting. Shown are representative results from 2 donors, a total of 7 donors were evaluated. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/s41598-018-32705-7), licensed under a CC-BY license.")
| Reactivity | Hu, Mu, Xp, RtSpecies Glossary |
| Applications | WB, IHC, ChIP |
| Clonality | Polyclonal |
| Host | Rabbit |
| Conjugate | Unconjugated |
| Immunogen | This antibody was developed against Recombinant Protein corresponding to amino acids: MEVLESGEQGVLQWDRKLSELSEPGDGEALMYHTHFSELLDEFSQNVLGQLLNDPFLSEKSVSMEVEPSPTSPAPLIQAEHSYSLCEEPRAQSPFTHITTSDSFND |
| Predicted Species | Rat (92%). Backed by our 100% Guarantee. |
| Isotype | IgG |
| Clonality | Polyclonal |
| Host | Rabbit |
| Gene | CREB3L2 |
| Purity | Immunogen affinity purified |
| Innovator's Reward | Test in a species/application not listed above to receive a full credit towards a future purchase. |
| Dilutions |
|
||
| Application Notes | For IHC-Paraffin, HIER pH 6 retrieval is recommended. |
||
| Control Peptide |
|
||
| Publications |
|
| Storage | Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles. |
| Buffer | PBS (pH 7.2) and 40% Glycerol |
| Preservative | 0.02% Sodium Azide |
| Purity | Immunogen affinity purified |
![Immunohistochemistry-Paraffin IRE1 alpha [p Ser724] Antibody - BSA Free](https://images.novusbio.com/images/IRE1-alpha-[p-Ser724]-Antibody-Immunohistochemistry-Paraffin-NB100-2323-img0025.jpg)
![Western Blot IRE1 alpha [p Ser724] Antibody - BSA Free](https://images.novusbio.com/images/IRE1-alpha-[p-Ser724]-Antibody-Western-Blot-NB100-2323-img0027.jpg)
![Western Blot IRE1 alpha [p Ser724] Antibody - BSA Free](https://images.novusbio.com/images/IRE1-alpha-[p-Ser724]-Antibody-Western-Blot-NB100-2323-img0029.jpg)
![Western Blot IGF-I R/IGF1R Antibody (33255) [Unconjugated]](https://images.novusbio.com/images2/IGF-I_R_MAB391_Western_Blot_6136.jpg)
![Immunohistochemistry IGF-I R/IGF1R Antibody (33255) [Unconjugated]](https://images.novusbio.com/images2/IGFI_R_MAB391_Immunohistochemistry_21743.jpg)
![Flow Cytometry IGF-I R/IGF1R Antibody (33255) [Unconjugated]](https://images.novusbio.com/images2/IGFI_R_MAB391_Flow_Cytometry_22536.jpg)
Secondary Antibodies |
Isotype Controls |
Research Areas for CREB3L2 Antibody (NBP1-88697)Find related products by research area.
|
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
| Gene Symbol | CREB3L2 |
![Immunohistochemistry-Paraffin: CREB3L2 Antibody [NBP1-88697] - Staining of human stomach shows moderate cytoplasmic positivity in glandular cells.](http://images.novusbio.com/fullsize/CREB3L2-Antibody-Immunohistochemistry-Paraffin-NBP1-88697-img0011.jpg "Immunohistochemistry-Paraffin: CREB3L2 Antibody [NBP1-88697] - Staining of human stomach shows moderate cytoplasmic positivity in glandular cells.")
![Western Blot: CREB3L2 Antibody [NBP1-88697] - Analysis in control (vector only transfected HEK293T lysate) and CREB3L2 over-expression lysate (Co-expressed with a C-terminal myc-DDK tag (3.1 kDa) in mammalian HEK293T cells).](http://images.novusbio.com/fullsize/CREB3L2-Antibody-Western-Blot-NBP1-88697-img0006.jpg "Western Blot: CREB3L2 Antibody [NBP1-88697] - Analysis in control (vector only transfected HEK293T lysate) and CREB3L2 over-expression lysate (Co-expressed with a C-terminal myc-DDK tag (3.1 kDa) in mammalian HEK293T cells).")
![Western Blot: CREB3L2 Antibody [NBP1-88697] - Expression of CREB3L2 in differentiating primary human B-cells. Protein expression of CREB3L2 during in vitro differentiation of primary human B-cells. The day of culture is indicated at the top. Intact and dashed arrows show migration of full-length protein and cleaved C-terminus, respectively. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/s41598-018-32705-7), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CREB3L2-Antibody-Western-Blot-NBP1-88697-img0007.jpg "Western Blot: CREB3L2 Antibody [NBP1-88697] - Expression of CREB3L2 in differentiating primary human B-cells. Protein expression of CREB3L2 during in vitro differentiation of primary human B-cells. The day of culture is indicated at the top. Intact and dashed arrows show migration of full-length protein and cleaved C-terminus, respectively. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/s41598-018-32705-7), licensed under a CC-BY license.")
![Immunohistochemistry-Paraffin: CREB3L2 Antibody [NBP1-88697] - Staining of human placenta shows strong nuclear and cytoplasmic positivity in trophoblastic cells.](http://images.novusbio.com/fullsize/CREB3L2-Antibody-Immunohistochemistry-Paraffin-NBP1-88697-img0003.jpg "Immunohistochemistry-Paraffin: CREB3L2 Antibody [NBP1-88697] - Staining of human placenta shows strong nuclear and cytoplasmic positivity in trophoblastic cells.")
![Immunohistochemistry-Paraffin: CREB3L2 Antibody [NBP1-88697] - Staining of human kidney shows strong cytoplasmci positivity in cells in tubules.](http://images.novusbio.com/fullsize/CREB3L2-Antibody-Immunohistochemistry-Paraffin-NBP1-88697-img0009.jpg "Immunohistochemistry-Paraffin: CREB3L2 Antibody [NBP1-88697] - Staining of human kidney shows strong cytoplasmci positivity in cells in tubules.")
![Immunohistochemistry-Paraffin: CREB3L2 Antibody [NBP1-88697] - Staining of human fallopian tube shows moderate cytoplasmic positivity in glandular cells.](http://images.novusbio.com/fullsize/CREB3L2-Antibody-Immunohistochemistry-Paraffin-NBP1-88697-img0010.jpg "Immunohistochemistry-Paraffin: CREB3L2 Antibody [NBP1-88697] - Staining of human fallopian tube shows moderate cytoplasmic positivity in glandular cells.")
![Western Blot: CREB3L2 Antibody [NBP1-88697] - S1P inhibition induces autophagy & affects multiple UPR-related TFs. (A) In vitro day 3 B-cells were treated with 10 μM PF-429242 or vehicle control (dH2O) for 72 h & were assessed for cell number using CountBright beads. Shown are the average cell numbers from 7 donors ± standard deviations. Protein lysates generated from day 3 cells treated for 72 h with 10 μM PF-429242 were evaluated for (B) autophagy markers or (C) CREB3L2 & ATF6 by Western blotting. Shown are representative results from 2 donors, a total of 7 donors were evaluated. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30254311), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-88697_rabbit-polyclonal-creb3l2-antibody-310202415304281.jpg "Western Blot: CREB3L2 Antibody [NBP1-88697] - S1P inhibition induces autophagy & affects multiple UPR-related TFs. (A) In vitro day 3 B-cells were treated with 10 μM PF-429242 or vehicle control (dH2O) for 72 h & were assessed for cell number using CountBright beads. Shown are the average cell numbers from 7 donors ± standard deviations. Protein lysates generated from day 3 cells treated for 72 h with 10 μM PF-429242 were evaluated for (B) autophagy markers or (C) CREB3L2 & ATF6 by Western blotting. Shown are representative results from 2 donors, a total of 7 donors were evaluated. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30254311), licensed under a CC-BY license. Not internally tested by Novus Biologicals.")
![Western Blot: CREB3L2 Antibody [NBP1-88697] - Kinetic & dose analysis of S1P-specific inhibitor PF-429242 during the early phase of ASC generation. (A) In vitro activated human B-cells were treated with 10 μM PF-429242 or vehicle control (dH2O) at day 3 & assessed for CREB3L2 processing at 12 h intervals. Representative results are shown from a total of 7 donors. (B) Samples from part (A) were assessed for cell number at the indicated time points. Displayed are the average cell number ± standard deviation derived from 7 donors. (C) In vitro activated human B-cells from 4 donors were treated with indicated amount PF-429242 or vehicle control (dH2O) at day 3 & assessed for cell number at 48 h. Results are displayed as the percentage viable cells relative to control. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30254311), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-88697_rabbit-polyclonal-creb3l2-antibody-310202415382439.jpg "Western Blot: CREB3L2 Antibody [NBP1-88697] - Kinetic & dose analysis of S1P-specific inhibitor PF-429242 during the early phase of ASC generation. (A) In vitro activated human B-cells were treated with 10 μM PF-429242 or vehicle control (dH2O) at day 3 & assessed for CREB3L2 processing at 12 h intervals. Representative results are shown from a total of 7 donors. (B) Samples from part (A) were assessed for cell number at the indicated time points. Displayed are the average cell number ± standard deviation derived from 7 donors. (C) In vitro activated human B-cells from 4 donors were treated with indicated amount PF-429242 or vehicle control (dH2O) at day 3 & assessed for cell number at 48 h. Results are displayed as the percentage viable cells relative to control. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30254311), licensed under a CC-BY license. Not internally tested by Novus Biologicals.")
![Western Blot: CREB3L2 Antibody [NBP1-88697] - S1P-specific inhibitor PF-429242 blocks CREB3L2 processing. (A) Diagram of CREB3L2 structure with proteolytic cleavage sites. Act domain, Activation Domain. bZIP, Basic Leucine Zipper Domain. TM, Transmembrane Domain. (B) In vitro generated human ASCs were treated with 10 μM PF-429242 or vehicle control (dH2O) on the day that appears first (d6, d8, d10) & protein lysates generated on the day that appears subsequently (d8, d10, d13) were analyzed by Western blotting. Intact & dashed arrows show migration of CREB3L2 full-length protein & cleaved C-terminus, respectively. (C) In vitro differentiated human B-cells were treated with 10 μM PF-429242 or vehicle control (dH2O) at day 6 & analyzed subsequently for phenotype on the indicated days. Live cells were evaluated for expression of B-cell markers CD19 & CD20 & ASC markers CD38 & CD138. Percentages of cells are shown within the quadrant gates. The experiment was performed with 4 donors, a representative donor is shown. (D) Samples treated as in part (B) were assessed for cell number using CountBright beads. (E) In vitro activated human B-cells from 4 donors were treated with indicated amount PF-429242 or vehicle control (dH2O) at day 6 & assessed for cell number at 48 h. Results are displayed as the percentage viable cells relative to control. Supernatants from samples in part (B) were analyzed by ELISA for production of (F) IgM & (G) IgG. Significance was determined by t-test. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30254311), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-88697_rabbit-polyclonal-creb3l2-antibody-310202416121935.jpg "Western Blot: CREB3L2 Antibody [NBP1-88697] - S1P-specific inhibitor PF-429242 blocks CREB3L2 processing. (A) Diagram of CREB3L2 structure with proteolytic cleavage sites. Act domain, Activation Domain. bZIP, Basic Leucine Zipper Domain. TM, Transmembrane Domain. (B) In vitro generated human ASCs were treated with 10 μM PF-429242 or vehicle control (dH2O) on the day that appears first (d6, d8, d10) & protein lysates generated on the day that appears subsequently (d8, d10, d13) were analyzed by Western blotting. Intact & dashed arrows show migration of CREB3L2 full-length protein & cleaved C-terminus, respectively. (C) In vitro differentiated human B-cells were treated with 10 μM PF-429242 or vehicle control (dH2O) at day 6 & analyzed subsequently for phenotype on the indicated days. Live cells were evaluated for expression of B-cell markers CD19 & CD20 & ASC markers CD38 & CD138. Percentages of cells are shown within the quadrant gates. The experiment was performed with 4 donors, a representative donor is shown. (D) Samples treated as in part (B) were assessed for cell number using CountBright beads. (E) In vitro activated human B-cells from 4 donors were treated with indicated amount PF-429242 or vehicle control (dH2O) at day 6 & assessed for cell number at 48 h. Results are displayed as the percentage viable cells relative to control. Supernatants from samples in part (B) were analyzed by ELISA for production of (F) IgM & (G) IgG. Significance was determined by t-test. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30254311), licensed under a CC-BY license. Not internally tested by Novus Biologicals.")
![Western Blot S100A10 Antibody [Unconjugated]](https://images.novusbio.com/images2/S100A10_AF2377_Western_Blot_17324.jpg)
![Immunohistochemistry S100A10 Antibody [Unconjugated]](https://images.novusbio.com/images2/S100A10_AF2377_Immunohistochemistry_17440.jpg)
![Simple Western S100A10 Antibody [Unconjugated]](https://images.novusbio.com/images2/S100A10_AF2377_Simple_Western_18705.jpg)
![Western Blot PERK Antibody [Unconjugated]](https://images.novusbio.com/images2/PERK_AF3999_Western_Blot_5379.jpg)
![Knockout Validated PERK Antibody [Unconjugated]](https://images.novusbio.com/images2/PERK_AF3999_Knockout_Validated_22482.jpg)
![Western Blot PERK Antibody [Unconjugated]](https://images.novusbio.com/images/af3999_human-perk-affinity-purified-polyclonal-ab-4120241240258.jpg)
![N/A CREB [p Ser133] [Biotin]](https://images.novusbio.com/images2/dyc2510-2_human-mouse-rat-phospho-creb-s133-duoset-ic-elisa-2-plate-712021221341.png)
![N/A CREB [p Ser133] [Biotin]](https://images.novusbio.com/images2/dyc2510-2_human-mouse-rat-phospho-creb-s133-duoset-ic-elisa-2-plate-712021221447.png)
![N/A CREB [p Ser133] [Biotin]](https://images.novusbio.com/images2/dyc2510-2_human-mouse-rat-phospho-creb-s133-duoset-ic-elisa-2-plate-712021221551.png)
![Bioactivity GDNF [Unconjugated]](https://images.novusbio.com/images2/GDNF_212GD_2846.jpg)
![SDS-PAGE GDNF [Unconjugated]](https://images.novusbio.com/images2/GDNF_212-GD_62.jpg)
![SEC-MALS GDNF [Unconjugated]](https://images.novusbio.com/images/212-gd_recombinant-human-gdnf-protein-sec-mals-25202393740..jpg)
![Immunohistochemistry Galectin-4 Antibody [Unconjugated]](https://images.novusbio.com/images/antibody/af2128_mouse-galectin-4-affinity-purified-polyclonal-ab-immunohistochemistry-29122022154254.jpg)
![Enzyme Activity u-Plasminogen Activator/Urokinase [Unconjugated]](https://images.novusbio.com/images2/uPlasminogen_Activator_1310SE_1837.jpg)
![Western Blot: Goat anti-Rabbit IgG (H+L) Secondary Antibody [HRP] [NB7160] - Western blot showing vemurafenib treatment in BRAFV600E CRC cells inhibits fission mediator DRP1 with no significant effect on fusion proteins (Mfn1 & 2) using MFN-1 antibody (NBP1-51841) and corresponding secondary antibody, goat anti-rabbit IgG-HRP (NB7160). Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/33738242).](https://images.novusbio.com/images/Goat-anti-Rabbit-IgG-H+L-Secondary-Antibody-HRP-Western-Blot-NB7160-img0001.jpg "Western Blot: Goat anti-Rabbit IgG (H+L) Secondary Antibody [HRP] [NB7160] - Western blot showing vemurafenib treatment in BRAFV600E CRC cells inhibits fission mediator DRP1 with no significant effect on fusion proteins (Mfn1 & 2) using MFN-1 antibody (NBP1-51841) and corresponding secondary antibody, goat anti-rabbit IgG-HRP (NB7160). Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/33738242).")
![Flow Cytometry: Rabbit IgG Isotype Control [NBP2-24891] - Intracellular FACS analysis of mouse TLR6 polyclonal antibody (red), rabbit isotype control (green), RAW cells alone (shaded). Two micrograms of antibodies were used. Goat anti-rabbit FITC (Novus, 20302) was used as secondary.](https://images.novusbio.com/images/Rabbit--Mouse-IgG-Isotype-Control-Flow-Cytometry-NBP2-24891-img0001.jpg "Flow Cytometry: Rabbit IgG Isotype Control [NBP2-24891] - Intracellular FACS analysis of mouse TLR6 polyclonal antibody (red), rabbit isotype control (green), RAW cells alone (shaded). Two micrograms of antibodies were used. Goat anti-rabbit FITC (Novus, 20302) was used as secondary.")